Edition:
India

TapImmune Inc (TPIV.OQ)

TPIV.OQ on NASDAQ Stock Exchange Capital Market

3.10USD
15 Dec 2017
Change (% chg)

$-0.19 (-5.78%)
Prev Close
$3.29
Open
$3.27
Day's High
$3.30
Day's Low
$3.10
Volume
12,440
Avg. Vol
4,907
52-wk High
$5.35
52-wk Low
$2.62

Summary

Name Age Since Current Position

Peter Hoang

44 2017 President, Chief Executive Officer, Director

Michael Loiacono

48 2016 Chief Financial Officer, Chief Accounting Officer, Treasurer, Corporate Secretary

Mark Reddish

60 2014 Vice President Development

Richard Kenney

57 2017 Acting Chief Medical Officer

David Laskow-Pooley

58 2015 Director

Joshua Silverman

46 2016 Director

Sherry Grisewood

62 2013 Independent Director

Frederick Wasserman

62 2016 Independent Director

Biographies

Name Description

Peter Hoang

Mr. Peter L. Hoang is President, Chief Executive Officer, Director of the company. He brings over twenty years of investment banking, venture capital, immuno-oncology and public company executive management experience to TapImmune, serving most recently as Senior Vice President of Business Development and Strategy at Bellicum Pharmaceuticals. Previously, as the Managing Director of Innovations at TheUniversity of TexasMD Anderson Cancer Center, he headed the new venture formation and development effort for the institution. Before joining MD Anderson, Mr. Hoang was a senior investment banker, most recently as Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group. He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. He earned an M.B.A. with high honors distinction from the Anderson School of Management atUCLAand a B.A. from Yale University. Mr. Hoang has also been appointed as a member of TapImmune's Board of Directors, and in connection with this appointment, the Board of Directors has expanded from six to seven members.

Michael Loiacono

Mr. Michael J. Loiacono is the Chief Financial Officer, Chief Accounting Officer, Treasurer, Corporate Secretary of the Company. Mr. Loiacono served as CFO of Global Axcess Corporation, a publicly-traded company, from 2006-2013 where he was responsible for the overall strategy of the company including capital raises, mergers & acquisitions, corporate finance, treasury, accounting and investor relations. Upon the acquisition of Global Axcess by FCTI, Inc., he was responsible for the company’s strategic development including new products and services, entrance into new markets and maximizing gross and net revenues. In 2009, he was named “Jacksonville Florida Ultimate CFO of the year” by the Jacksonville Business Journal. Prior to Global Axcess/FCTI Mr. Loiacono held various positions of increasing responsibility in finance management through several private and publicly-traded organizations. He has a degree in Business Management from Rutgers University, Business School, NJ.

Mark Reddish

Mr. Mark Reddish has been appointed as Vice President Development of Tapimmune Inc., effective April 30, 2012. He was formerly Vice President of Product Development and Principal Investigator, Biodefense at ID Biomedical, Bothell, WA, prior to the acquisition of the company by Glaxo SmithKline for $1.6 billion. At Biomira Inc, (renamed Oncothyreon) he was responsible for preclinical development of their cancer vaccines program where he led the early research and clinical development of Stimuvax, which is currently in late Stage 3 clinical trials under a partnership with Merck KGa. In 2007, Mark started a consultancy business where he advised pharmaceutical companies such as AI Biopharma, BMG Hematology and PriTest. He brings thirty years of biomedical experience ranging from clinical and academic research to industrial product development and has already brought value and insight to the company as a member of the scientific advisory board. He has over 50 publications and a number of issued and pending patents in the area of vaccine technologies.

Richard Kenney

Dr. Richard T. Kenney has been appointed Acting Chief Medical Officer of the Company. Dr. Kenney also serves as President of ClinReg Biologics, LLC, his own clinical consulting firm. Prior to this role, Dr. Kenney served as Principal Medical Advisor and Chief Medical Officer of Immune Design, where he led the clinical development, pharmacovigilance and regulatory affairs groups to advance the development and commercialization of the company's prime-boost immunotherapeutic vaccines. Previously, Dr. Kenney served as Chief Medical Officer of Crucell Holland, BV, where he directed the development of a broad platform of vaccines, and as Senior Vice President, Clinical Development for Vical Incorporated, where he led the clinical development of DNA vaccines for cancer immunotherapy and infectious diseases. Dr. Kenney held key positions in vaccine development at GSK Biologicals from 2005 to 2009, most recently as Senior Director of Global Clinical R&D, Vaccines for Viral Diseases. He earned his M.D. degree at Harvard Medical School, then completed his residency in Internal Medicine at Duke University Medical Center and a fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases.

David Laskow-Pooley

Mr. David Laskow-Pooley is Director of TapImmune Inc. Mr. Laskow-Pooley is currently CEO of London Pharma Ltd, a clinical stage company re-purposing approved drugs through novel drug delivery technologies and is the Co-founder of Pharmafor Ltd. He was formerly Managing Director (UK) of Nasdaq- listed drug discovery platform company, OSI, and was part of the corporate team that developed and launched Tarceva for the treatment of lung cancer with marketing partners Roche and Genentech. He has had a distinguished career in multinational pharmaceutical companies including Glaxo SmithKline and Abbott, in addition to InVitrogen (Biotech Life Sciences) and Amersham, now GE Healthcare (Diagnostic Imaging). He currently serves as a non-executive director and Chairman of OBN Ltd, the leading industry representative for small to medium enterprises (SME's) in the UK.

Joshua Silverman

Mr. Joshua N. Silverman serves as Director of the Company. Mr. Silverman is currently and has been the Co–founder and Managing Member of Parkfield Funding LLC, an investment and consulting firm, since August 1, 2016. Mr. Silverman was a former Principal and Managing Partner of Iroquois Capital Management, LLC (“Iroquois”), where he served as Co–Chief Investment Officer of Iroquois from 2003 until August 1, 2016. From 2000 to 2003, Mr. Silverman served as Co–Chief Investment Officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as Assistant Press Secretary to The President of The United States. Mr. Silverman received his B.A. from Lehigh University in 1992. In the past five years, Mr. Silverman has served on the boards of directors of Neurotrope, Inc., MGT Capital Investments Inc., National Holdings Corporation, Alanco Technologies Inc., Protagenic Therapuetics, Inc. and WPCS International Incorporated.

Sherry Grisewood

Ms. Sherry Grisewood, CFA, has been appointed as Independent Director of TapImmune Inc., effective March 20, 2013. She has over 25 years securities industry experience in a range of investment banking, advisory and research-related activities. She currently has a senior banking and banking analytical role at Dawson James Securities. Prior to joining Dawson James, she was Managing Director, Lifesciences and Technology Banking for Tripoint Global Equities. Sherry served as Senior Life Sciences Banker at Jesup & Lamont Securities Corp. and as an independent strategic advisor and consultant for several investment banks over the prior 12 year period. She has participated in over 50 transaction-related projects worldwide involving initial public offerings, secondary offerings, PIPE's, private equity, M&A and licensing transactions in the life sciences sector. Prior to consulting for investment banks, Sherry served as Director of Research for several mid-tier brokerage companies and a independent investment research company. She has been an advisor to TapImmune since 2011. Sherry has a Bachelor of Science degree in Life Science (Highest Honors) from Ramapo College of New Jersey. She is a member of the American Society of Gene and Cell Therapy, the Tissue Engineering and Regenerative Medicine Society International, the Society of Biomaterials, the CFA Institute and the NY Society of Security Analysts.

Frederick Wasserman

Mr. Frederick G. Wasserman is Independent Director of the Company. Frederick (Rick) is an accomplished Board Director with 35 years of business experience. He has served during his career as President, COO and CFO of entrepreneurial, middle-market companies. Rick has a strong financial background which he has successfully focused on all aspects of company operations including cash flow, profitability and equity valuation. He has served as a member of Audit and Corporate Governance Committees for public companies in the U.S. and Europe. In his role as President of FGW Partners LLC, Pennington, New Jersey, he has assisted small and micro-cap companies at transitional points in their evolutions. This has included focus on corporate governance, investment analysis and liquidity management, as well as general financial and operational issues. Rick was a Certified Public Accountant who held staff positions through Audit Manager for three accounting firms. He has a B.S. in Economics from the Wharton School, University of Pennsylvania, PA.